The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data

Axel Le Cesne

doi:10.2217/fon-2022-0516

The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data

Axel Le Cesne

Résultats de recherche: Contribution à un journal › Brève enquête › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	1-3
Nombre de pages	3
journal	Future Oncology
Volume	18
Numéro de publication	30s
Les DOIs	https://doi.org/10.2217/fon-2022-0516
état	Publié - 1 janv. 2022
Modification externe	Oui

Accès au document

10.2217/fon-2022-0516

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{0be319d69f72448d839314998635449f,

title = "The role of trabectedin as second-line treatment of advanced soft tissue sarcoma: update of key efficacy and safety data",

keywords = "advanced soft tissue sarcoma, sarcoma guidelines, second-line treatment, trabectedin",

author = "{Le Cesne}, Axel",

note = "Funding Information: Writing assistance for this article was provided by K Lyseng-Williamson and K Dechant on behalf of Content Ed Net (Madrid, Spain) with funding from PharmaMar (Madrid, Spain). Open access ",

year = "2022",

month = jan,

day = "1",

doi = "10.2217/fon-2022-0516",

language = "English",

volume = "18",

pages = "1--3",

journal = "Future Oncology",

issn = "1479-6694",

number = "30s",

}

TY - JOUR

T1 - The role of trabectedin as second-line treatment of advanced soft tissue sarcoma

T2 - update of key efficacy and safety data

AU - Le Cesne, Axel

N1 - Funding Information: Writing assistance for this article was provided by K Lyseng-Williamson and K Dechant on behalf of Content Ed Net (Madrid, Spain) with funding from PharmaMar (Madrid, Spain). Open access

PY - 2022/1/1

Y1 - 2022/1/1

KW - advanced soft tissue sarcoma

KW - sarcoma guidelines

KW - second-line treatment

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=85142402236&partnerID=8YFLogxK

U2 - 10.2217/fon-2022-0516

DO - 10.2217/fon-2022-0516

M3 - Short survey

C2 - 36200943

AN - SCOPUS:85142402236

SN - 1479-6694

VL - 18

SP - 1

EP - 3

JO - Future Oncology

JF - Future Oncology

IS - 30s

ER -